Sanofi's lixisenatide adds to effectiveness of insulin glargine in type 2 diabetes

15 September 2016

Sanofi (Euronext: SAN) has presented new data suggesting that a fixed-ratio combination of lixisenatide and insulin glargine, known as iGlarLixi, helps more diabetes patients with type 2 diabetes to reach mealtime blood sugar targets than insulin glargine alone.

The French drug major is presenting new results from the pivotal Phase III study LixiLan-L at this week’s European Association for the Study of Diabetes (EASD) 52nd Annual Meeting.

Mike Baxter, consultant advisor to Sanofi Diabetes UK, said: “Blood glucose management in the UK is among the worst in Europe with, on average, people with type 2 diabetes having the highest blood glucose levels compared to nine other developed countries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK